IQV: Stock thesis & analysis
As of 09-01-2026
📁 From our research archive: this thesis was generated on 09-01-2026 and may not reflect our current view. See the latest research →
IQV is a leading CRO franchise with respectable ROE (22.8%) and FCF margin (12.7%), but quality score is middling (40/100), D/E is elevated at 258%, and op margins are unremarkable for a scale player in clinical research services. Institutional coverage is thin (1 tracked holder, under-followed) — plausibly structural given the name's size and long-only mandate fit, but with no recent fund initiations and two insider sales in the last month, there is no confirming signal to offset the leverage and margin concerns. With late-cycle credit conditions flagged and no analyst or catalyst tailwind, this is a pass rather than a stretch entry.
Catalysts to watch
- Next quarterly earnings report — watch for op margin trajectory and bookings/backlog trends
- Potential resumption of analyst coverage or upgrades given health care sector leadership
- M&A or biopharma R&D spending recovery could lift CRO outsourcing volumes
Key risks
- High leverage (D/E ~258%) leaves limited balance sheet flexibility in a slower-growth environment
- Quality score (40/100) reflects margin structure below best-in-class peers
- No smart-money confirmation and no recent analyst activity to validate a re-rating catalyst
- Insider selling (two transactions, ~$1.7M) in the last 30 days, though likely diversification-driven
What would change the view
- Stock breaks below $225.00
- Op margin falls below 11% for 2 consecutive quarters
- D/E rises above 300% without a clear deleveraging plan disclosed